Mediwelcome Healthcare Management & Technology
Open-offer-subscription Rate: 168.8x One Lot Success Rate: 15%
Mediwelcome Healthcare Management & Technology is provider in the Integrated Healthcare Marketing Solutions Market in China.
It primarily provides (i) medical conference services, (ii) patient education and screening services, and (iii)marketing strategy and consulting services, and also began to offer CRO services in late 2019 which primarily consist of patients' recruitment and clinical data collection services, and internet hospital services which mainly provide online follow up consultation to the physicians' existing patients and e-prescription service.
To boost its patient education and screening capabilities, it developed and launched the Online Conference Assistant , a WeChat mini-program that assists physicians in organizing and managing onsite patient education classes, as well as various WeChat public accounts where patients can find self-management support through watching educational videos, reading disease-related educational articles and conducting disease risk screening. It also have launched the Conference+ App for users, i.e. medical NGOs and pharmaceutical companies, to submit onsite conference requests and monitor conference implementation.
Its integrated healthcare marketing solutions are principally provided to China's esteemed medical NGOs and well-known pharmaceutical companies, it also serves medical device companies, healthcare and pharmaceutical publications and hospitals. It have developed a network of approximately 24,000 CCVD physicians as of June 30, 2020, among which over 70% worked for Grade 3 hospitals in China.
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Website | www.mediwelcome.com |
| Board Lot | 800 |
| Registrar & Transfer Office | Computershare Hong Kong Investor Services |
| No. of Offer Shares | 50.00m shares |
| No. of International Offer Shares | 45.00m shares |
| No. of HK Offer Shares | 5.00m shares |
| Offer Price | $3.00 - $4.00 |
| Nominal Value | HK$ 0.00001 each |
| Stock Code | 2159 |
| Sole Sponsor and Sole Global Coordinator | CEB International Capital |
| Joint Bookrunners | CEB International Capital, Aristo Securities, BOCOM International Securities, CMBC Securities, SPDB International Capital |
| Joint Lead managers | CEB International Capital, Aristo Securities, BOCOM International Securities, CMBC Securities, Ruibang Securities, SPDB International Capital, Wonderland International Securities |
| Application Period | Dec 31 (Thu) - Noon, Jan 8 (Fri) |
| Price Determination Date | On or Before 5pm, Jan 8 (Fri) |
| Result Announcement Date | On or Before Jan 18 (Mon) |
| Dispatch of Shares and Refund Cheques | On or Before Jan 18 (Mon) |
| Dealings in Shares commence on | Jan 19, 2021. (Tue) |
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
| Executive | Shi Wei (Chairman), Yang Weimin, Wang Liang, He Jiyong, Wang Wei, Sui Huijun |
| Non-Executive | Zhang Yitao, Liu Xia |
| Independent Non-Executive | Song Ruilin, Xiang Fei John, Wang Zheng David, Yang Xiaoxi |
| Shi Wei | 20.33% |
| Yang Weimin | 12.70% |
| Zhang Yitao | 12.70% |
| Wang Liang | 6.02% |
| (Year ended Dec 31) | |||
| 2020 * | 2019 | 2018 | |
| Revenue | 138,681 | 427,159 | 298,968 |
| Gross Profit | 28,132 | 94,868 | 84,596 |
| Pre-Taxed Profit | (4,568) | 25,972 | 49,152 |
| Attributable Profit for the period | (2,278) | 20,852 | 38,041 |
| * For the six months ended June 30, 2020. | |||
| Attributable Profit (not less than) | 21m |
| Unaudited pro forma EPS | 11 cents |
| Offer Price | $3.00 - $4.00 |
| Capitalization | $600m - $800m |
| Unaudited pro forma adj NAV / share | $1.21 - $1.43 |
| Assuming the offer price being at the mid-point of $3.50, the net proceeds raised would be HK$110.8m, of which: |
| * $64.3m (58.0%) use to broaden its customer base, disease area coverage and patient base ; |
| * $27.7m (25.0%) use to complement its service capabilities through the development of internet hospital services ; |
| * $13.3m (12.0%) use for its working capital and general corporate purposes; |
| * $5.5m (5.0%) use to further expand its CRO services. |
| 19/01/2021 16:08 |
| {New Stock}MEDIWELCOME(02159) ends up 26.33% at HK$3.79 |
| 19/01/2021 09:20 |
| {New Stock}MEDIWELCOME(02159) opens up 33.33% at HK$4 |
| Code | Name | Nominal | Change | %Change | |
| 02159 | MEDIWELCOME |  | 2.770 | -0.050 | -1.773% |
| 09906 | HONLIV HEALTH |  | 1.820 | 0.000 | 0.000% |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). | |
| Quote data is at least 15-min delayed，last updated: 14/04/2021 11:01 |
Subscription --
Result Announcement -- 
Listing --Offer Price︰--
| Currency | : |
| Listing Price | |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |